PT3380522T - Moléculas de anticorpos contra april e suas utilizações - Google Patents
Moléculas de anticorpos contra april e suas utilizaçõesInfo
- Publication number
- PT3380522T PT3380522T PT168101954T PT16810195T PT3380522T PT 3380522 T PT3380522 T PT 3380522T PT 168101954 T PT168101954 T PT 168101954T PT 16810195 T PT16810195 T PT 16810195T PT 3380522 T PT3380522 T PT 3380522T
- Authority
- PT
- Portugal
- Prior art keywords
- april
- antibody molecules
- antibody
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259897P | 2015-11-25 | 2015-11-25 | |
| US201662313684P | 2016-03-25 | 2016-03-25 | |
| US201662399087P | 2016-09-23 | 2016-09-23 | |
| US201662422848P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3380522T true PT3380522T (pt) | 2024-02-14 |
Family
ID=57543212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT168101954T PT3380522T (pt) | 2015-11-25 | 2016-11-23 | Moléculas de anticorpos contra april e suas utilizações |
Country Status (27)
| Country | Link |
|---|---|
| US (9) | US20170145086A1 (https=) |
| EP (2) | EP3380522B1 (https=) |
| JP (4) | JP2019506363A (https=) |
| KR (2) | KR20250008787A (https=) |
| CN (3) | CN109089419B (https=) |
| AU (1) | AU2016361488B2 (https=) |
| CA (1) | CA3006058A1 (https=) |
| CL (2) | CL2018001372A1 (https=) |
| CO (1) | CO2018006461A2 (https=) |
| DK (1) | DK3380522T5 (https=) |
| ES (1) | ES2970864T3 (https=) |
| FI (1) | FI3380522T3 (https=) |
| HK (1) | HK1254337A1 (https=) |
| HR (1) | HRP20231578T1 (https=) |
| HU (1) | HUE064791T2 (https=) |
| IL (2) | IL259585B2 (https=) |
| LT (1) | LT3380522T (https=) |
| MA (1) | MA43308A (https=) |
| MX (2) | MX2018006385A (https=) |
| MY (1) | MY197345A (https=) |
| PL (1) | PL3380522T3 (https=) |
| PT (1) | PT3380522T (https=) |
| SA (1) | SA518391659B1 (https=) |
| SG (1) | SG11201804309PA (https=) |
| SI (1) | SI3380522T1 (https=) |
| WO (1) | WO2017091683A1 (https=) |
| ZA (1) | ZA201803366B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210340266A1 (en) * | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| AU2019417720A1 (en) * | 2018-12-24 | 2021-07-08 | Visterra, Inc. | Methods for identifying epitopes and paratopes |
| CA3131019A1 (en) | 2019-02-22 | 2020-08-27 | Memorial Sloan Kettering Cancer Center | Cd33 antibodies and methods of using the same to treat cancer |
| CN110522902B (zh) * | 2019-09-25 | 2022-10-11 | 南京农业大学 | 一种用于建立慢性肾病模型的组合物及其应用 |
| JP7686000B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
| IL296358A (en) * | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CA3187823A1 (en) * | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2022081716A1 (en) * | 2020-10-13 | 2022-04-21 | Accubit LLC - Biotechnology | Methods of treating iga nephropathy with thiol-containing molecules |
| EP4237003A4 (en) | 2020-10-28 | 2025-07-09 | Janssen Biotech Inc | COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY |
| CN112730851B (zh) * | 2021-03-31 | 2021-06-22 | 南京立顶医疗科技有限公司 | 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒 |
| AU2022269411A1 (en) * | 2021-05-04 | 2023-12-21 | Immunorizon Ltd. | Anti-nkg2d antibodies and uses thereof |
| US20240279310A1 (en) | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| KR20250099778A (ko) | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
| CN119930816A (zh) * | 2023-11-02 | 2025-05-06 | 广东菲鹏制药股份有限公司 | 抗cd39人源化抗体或其抗原结合片段及其应用 |
| WO2026067804A1 (zh) * | 2024-09-30 | 2026-04-02 | 信立泰(成都)生物技术有限公司 | 一种抗april抗体或其抗原结合片段及用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| CZ294615B6 (cs) | 1997-09-12 | 2005-02-16 | Apotech R & D Sa | Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny |
| WO2001060397A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2001087977A2 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| EP1401870A4 (en) | 2001-05-24 | 2006-04-19 | Human Genome Sciences | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) |
| US20070249530A1 (en) | 2004-01-29 | 2007-10-25 | Genentech, Inc. | Bcma Polypeptides and Uses Thereof |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1934258B1 (en) * | 2005-09-26 | 2011-03-02 | Enzo Life Sciences (ELS) AG | Antibodies against april as biomarkers for early prognosis of lymphoma patients |
| CN101678106B (zh) | 2007-03-27 | 2013-06-05 | 津莫吉尼蒂克斯公司 | 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合 |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2203180B1 (en) * | 2007-10-22 | 2012-11-21 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| HUE028784T2 (en) * | 2008-05-01 | 2017-01-30 | Zymogenetics Inc | Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures |
| US20210340266A1 (en) | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CA2754127C (en) * | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| EP2488200A4 (en) | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| US8961967B2 (en) * | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| KR101871008B1 (ko) * | 2010-09-16 | 2018-06-25 | 발리오팜 아게 | 항-huTNFR1 항체 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| JP2016515120A (ja) * | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| EP3065774B1 (en) * | 2013-11-06 | 2021-05-26 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| WO2016113368A1 (en) | 2015-01-15 | 2016-07-21 | Universite Grenoble Alpes | Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer |
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| CN105390742A (zh) * | 2015-12-31 | 2016-03-09 | 石家庄圣泰化工有限公司 | 高电压锂离子电池电解液及其制备方法及应用 |
| WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
| CA3187823A1 (en) | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
-
2016
- 2016-11-23 FI FIEP16810195.4T patent/FI3380522T3/fi active
- 2016-11-23 JP JP2018526763A patent/JP2019506363A/ja not_active Ceased
- 2016-11-23 LT LTEPPCT/US2016/063518T patent/LT3380522T/lt unknown
- 2016-11-23 HU HUE16810195A patent/HUE064791T2/hu unknown
- 2016-11-23 MY MYPI2018000794A patent/MY197345A/en unknown
- 2016-11-23 HR HRP20231578TT patent/HRP20231578T1/hr unknown
- 2016-11-23 US US15/360,145 patent/US20170145086A1/en not_active Abandoned
- 2016-11-23 CN CN201680079727.0A patent/CN109089419B/zh active Active
- 2016-11-23 CA CA3006058A patent/CA3006058A1/en active Pending
- 2016-11-23 KR KR1020247042525A patent/KR20250008787A/ko active Pending
- 2016-11-23 SG SG11201804309PA patent/SG11201804309PA/en unknown
- 2016-11-23 PT PT168101954T patent/PT3380522T/pt unknown
- 2016-11-23 PL PL16810195.4T patent/PL3380522T3/pl unknown
- 2016-11-23 CN CN202410173851.XA patent/CN118027201A/zh active Pending
- 2016-11-23 HK HK18113413.2A patent/HK1254337A1/zh unknown
- 2016-11-23 IL IL259585A patent/IL259585B2/en unknown
- 2016-11-23 ES ES16810195T patent/ES2970864T3/es active Active
- 2016-11-23 EP EP16810195.4A patent/EP3380522B1/en active Active
- 2016-11-23 DK DK16810195.4T patent/DK3380522T5/da active
- 2016-11-23 WO PCT/US2016/063518 patent/WO2017091683A1/en not_active Ceased
- 2016-11-23 AU AU2016361488A patent/AU2016361488B2/en active Active
- 2016-11-23 CN CN202410173854.3A patent/CN118420760A/zh active Pending
- 2016-11-23 MA MA043308A patent/MA43308A/fr unknown
- 2016-11-23 EP EP23200975.3A patent/EP4285923A3/en active Pending
- 2016-11-23 SI SI201631788T patent/SI3380522T1/sl unknown
- 2016-11-23 KR KR1020187017534A patent/KR102747820B1/ko active Active
- 2016-11-23 MX MX2018006385A patent/MX2018006385A/es unknown
- 2016-11-23 IL IL313508A patent/IL313508A/en unknown
-
2018
- 2018-05-21 ZA ZA2018/03366A patent/ZA201803366B/en unknown
- 2018-05-22 CL CL2018001372A patent/CL2018001372A1/es unknown
- 2018-05-23 MX MX2024010175A patent/MX2024010175A/es unknown
- 2018-05-23 SA SA518391659A patent/SA518391659B1/ar unknown
- 2018-06-22 CO CONC2018/0006461A patent/CO2018006461A2/es unknown
- 2018-12-07 US US16/212,957 patent/US10385123B2/en active Active
-
2019
- 2019-06-28 US US16/456,810 patent/US20190330326A1/en not_active Abandoned
-
2020
- 2020-06-10 US US16/898,024 patent/US10954296B2/en active Active
- 2020-06-25 US US16/912,131 patent/US10968270B2/en active Active
- 2020-06-25 US US16/912,085 patent/US10981982B2/en active Active
- 2020-10-20 US US17/074,857 patent/US11136385B2/en active Active
-
2021
- 2021-08-16 JP JP2021132222A patent/JP7029018B2/ja active Active
- 2021-08-31 US US17/463,319 patent/US12091451B2/en active Active
-
2022
- 2022-02-17 JP JP2022022801A patent/JP2022068288A/ja not_active Withdrawn
-
2024
- 2024-01-30 CL CL2024000276A patent/CL2024000276A1/es unknown
- 2024-03-19 JP JP2024043460A patent/JP2024073611A/ja active Pending
- 2024-07-31 US US18/790,750 patent/US20250066464A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278803A (en) | PD-1 antibody molecules and their use | |
| IL259585A (en) | Antibody molecules for april and their uses | |
| IL271539A (en) | CD73 antibody molecules and their use | |
| IL251563A0 (en) | Antibody molecules to pd-l1 and their use | |
| ZA201604740B (en) | Antibody molecules to lag-3 and uses thereof | |
| SG11201605627TA (en) | Antibody molecules to tim-3 and uses thereof | |
| IL254517A0 (en) | Antibodies against muc16 and their uses | |
| ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201606624WA (en) | Antibody moleules to dengue virus and uses thereof | |
| ZA201704943B (en) | Antibodies to tau and uses thereof | |
| GB201522391D0 (en) | Antibody molecules | |
| GB201503812D0 (en) | Antibody molecules and uses thereof | |
| IL251676A0 (en) | Antibodies that bind to ccr6 and their uses | |
| SG11201705748SA (en) | Anti-glycoprotein antibodies and uses thereof | |
| GB201307501D0 (en) | Anti-fungal antibody molecules and uses thereof | |
| IL252932A0 (en) | Anti-cxcl12 antibody molecules and their uses | |
| HK1262462A1 (en) | Antibody molecules to pd-1 and uses thereof | |
| GB201612534D0 (en) | Antibodies and related molecules and uses thereof | |
| GB201604378D0 (en) | Antibodies and related molecules and uses thereof |